Posts by Raymond T. Chung, MD
-
Monitoring Novel HBV Markers Worthwhile in HBeAg-positive Patients Coinfected With HIV
In a longitudinal study, Raymond T. Chung, MD, and colleagues in the Hepatitis B (HBV) Research Network demonstrated a clear relationship between the novel biomarkers HBV RNA and HBcrAg—and by inference HBV transcription status—in HBeAg-positive but not HBeAg-negative patients with HBV–HIV coinfection.
-
Molecular Signature Predicts Progression of Early-stage Liver Fibrosis
Raymond T. Chung, MD, vice chief of the Division of Gastroenterology and director of Hepatology and the Liver Center, and colleagues defined a molecular signature that predicts progression of early-stage liver fibrosis within five years in an etiology-agnostic manner, which can inform anti-fibrotic drug development.
-
Review: Liver Disease in HCV/HIV Coinfection
Andre J. Jeyarajan and Raymond T. Chung, MD, of the Division of Gastroenterology, explain why clearance of the hepatitis C virus is insufficient to prevent further liver damage and progression in HCV/HIV coinfected patients.
-
MGH Research Scholars Respond to COVID-19
This video highlights how the MGH Research Scholars rapidly mobilized to address key medical and scientific challenges posed by COVID-19.
-
AASLD Consensus Statement Advises on Liver Disease Treatment During the COVID-19 Pandemic
A regularly updated consensus statement provides information on what is currently known about COVID-19 and how it may impact hepatologists, liver transplant providers and their patients.
-
Elevations in Aminotransferases Mirror Severity of COVID-19
The pattern of liver biochemistries in COVID-19 is notable for elevation in aspartate aminotransferase, possibly reflecting a unique virally mediated mechanism of hepatic injury.
-
Use of PEG-IFN-Lambda to Treat COVID-19: Q&A with Raymond Chung, MD
Pegylated interferon lambda (PEG-IFN-lambda) is a potent antiviral cytokine that acts to generate an antiviral state within many cell types. In this Q&A, Raymond Chung, MD, explains what is currently known about PEG-IFN-lambda therapy and why he is excited about its potential to treat COVID-19 patients.
-
Fecal Microbiota Transplant Cures Most Patients with C. Difficile Who Also Have Cirrhosis
Patients with cirrhosis who have recurrent or refractory Clostridium difficile infection are likely to be cured with oral frozen fecal microbiota transplant but may need more capsules than noncirrhotic patients do.
-
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Editorial: Direct-acting Antiviral Treatment for Hepatitis C Significantly Reduces Long-Term Complications
Commenting on a large, prospective French study, gastroenterology experts at Massachusetts General Hospital believe that direct-acting, oral antiviral therapy reduces the risk of complications of the hepatitis C virus and should be recommended to all chronically infected patients.
Biography
Raymond Chung, MD is the Director of Hepatology and Liver Center at Massachusetts General Hospital and a Associate Professor of Medicine at Harvard Medical School. Dr. Chung completed his B.A. at Harvard College and his MD from Yale University School of Medicine. He completed a residency in Internal Medicine and a fellowship in Gastroenterology and Hepatology at the Massachusetts General Hospital.
Dr. Chung’s focus has been fundamental and translational research in HCV infection. Major focus of his research has been elucidating the basis for the observed accelerated liver disease pathogenesis in HCV-HIV coinfection. In this regard his research has made important contributions to the current understanding of hepatic pathogenesis of coinfection.
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.